Chaperone Therapeutics
company
About
Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding
- 11 - 50
Highlights
Details
- Last Funding Type
- Grant
- Industries
- Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2009
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding: the underlying causes of neurodegenerative and other rare diseases.Their therapeutic approaches elevate the natural protein folding and stress protection mechanisms to prevent protein misfolding and the ensuing cell dysfunction and death. Chaperone’s unique drug discovery platforms, broad knowledge in small molecule optimization and expertise in animal models of protein misfolding disease and clinical evaluation propel their therapeutic discovery programs forward.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
—
Chaperone Therapeutics has raised a total of
—
in funding over 2 rounds. Their latest funding was raised on
Sep 6, 2016 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 6, 2016 | Grant | — | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Chaperone Therapeutics is funded by 1 investors.
National Institutes of Health
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
National Institutes of Health
|
— | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
